Vasomune Therapeutics is a private biotechnology company developing therapies to target diseases associated with blood vessel (vascular) dysfunction and destabilization. The inner most layer of blood vessels is made up of individual endothelial cells that regulate the passage of immune cells to a site of injury. In many different disease states, dysfunctional vasculature results in an exaggerated inflammatory response. Vascular dysfunction can lead to, or exacerbate many different diseases such as cardiovascular, renal, pulmonary and oncology. The company’s lead compound is Vasculotide, a Tie2 receptor agonist that has demonstrated positive therapeutic effect in many different diseases associated with vascular dysfunction.
From its’ co-inventors, Dr. Paul Van Slyke and the late Dr. Daniel J. Dumont, Vasomune Therapeutics was spun out of MaRS Innovation and Sunnybrook Health Sciences Centre at the University of Toronto in 2012. Vasomune’s program focuses on targeting Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) and Acute Kidney Injury (AKI). While several distinct clinical paths exist for the development of Vasculotide, the decision to pursue ALI and AKI is based on strong, third-party validated preclinical data sets and converging evidence that vascular dysfunction lies at the core of these indications. Vasomune Therapeutics strives to translate its’ strong foundation of academic science into clinical practice.